Коррекция гиперфосфатемии при хронической почечной недостаточности: роль севеламера


Е.М. Шилов

Кафедра нефрологии и гемодиализа ФППОВ ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждается роль фосфат-байндеров, в частности, севеламера, в лечении нарушений фосфорно-кальциевого обмена при хронической болезни почек.

Литература



  1. National Kidney Foundation (NKF). K/DOQI clinical practice guidelines for bone metabolism and disease in chronickidney disease. Am J Kidney Dis. 2003; 42: S1—S201.

  2. Moe S., Chen N. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213—216.

  3. Amann K., Gross M.L., London G.M., Ritz E. Hyperphosphatemia: a silent killer in patients with renal failure. Nephrol Dial Transplant 1999; 14: 2085-2087.

  4. Guerin A.P., London G.M., Marchais S.J., Metivier F. Arterial stiffness and vacular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.

  5. Kramer H., Toto R., Peshock R. et al. Association between chronic kidney disease and coronary artery calcification. The Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513.

  6. Mehrotra A., Budoff M., Christenson P. et al. Determinants of coronary artery calcification in diabetics with andwithout nephropathy. Kidney Int. 2004; 66: 2022-2031.

  7. Suki W.N., Zabaneh R., Cangiano J.L. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.

  8. St. Peter W.L., Liu J., Weinhandl E., Fan Q. A comparison of sevelamer and calcium-based phosphate-binders on mortality, hospitalizations and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am JKidney Dis 2008; 51: 445-454.

  9. Block G.A., Raggi P., Bellasi A. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.

  10. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.

  11. Borzecki A.M., Lee A., Wang S.W. et al. Survival in end-stage renal disease: calcium carbonate vs sevelamer. J Clin Pharmacy & Ther. 2007; 32: 617-624.

  12. Tonelli M., Wiebe N., Culleton B. et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.

  13. Chertow G.M., Burke S.K., Raggi P. et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.

  14. Chertow G.M., Dillon M., Burke S.K. et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyreoidism in hemodyalisis patients. Clin Nephrol. 1999; 51: 18-26.

  15. Qunibi W., Moustafa M., Muenz L.R. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis 2008; 51: 952-965.

  16. Ferramosca E., Brucke S., Chasan-Taber S. et al. Potential antiatherogenic and anti-inflammatory prorepties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.

  17. Ketteler M., Rix M., Fan S. et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3:1125-1130.

  18. Evenepoel P. Control of hyperphosphatemia beyond phosphate. Kidney Int. 2007; 71: 376-379.


Об авторах / Для корреспонденции


Е.М. Шилов - д.м.н., профессор, заведующий кафедрой нефрологии и гемодиализа ФППОВ ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России
emshilov@yandex.ru


Похожие статьи


Бионика Медиа